SMTL ID : 7anq.1

Complete PCSK9 C-ter domain in complex with VHH P1.40

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.20 Å

Oligo State

hetero-1-1-mer

Ligands

1 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-FUC.1: 3 residues within 4Å: Chain A: N.82, Q.103, H.151 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:Q.103

1 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 6 residues within 4Å: Chain A: W.10, F.38, Y.197, R.206 Chain B: P.41, R.43 4 PLIP interactions: 1 interactions with chain B, 3 interactions with chain A Salt bridges: B:R.43, A:R.206 Hydrogen bonds: A:Y.197, A:Y.197

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Fruchart Gaillard, C. et al., Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels. Mol Metab (2022)

Release Date

2021-10-20

Peptides

Proprotein convertase subtilisin/kexin type 9: A
VHH P1.40 minibody anti-Cter PCSK9: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Proprotein convertase subtilisin/kexin type 9

VHH P1.40 minibody anti-Cter PCSK9